Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone
Background The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Journal of Investigative Surgery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/08941939.2020.1800871 |
| _version_ | 1797684530864193536 |
|---|---|
| author | Yannis Mesli Lise Holterbach Jean-Baptiste Delhorme Zaher Lakkis Pablo Ortega-Deballon Sophie Deguelte Serge Rohr Cécile Brigand Nicolas Meyer Benoit Romain |
| author_facet | Yannis Mesli Lise Holterbach Jean-Baptiste Delhorme Zaher Lakkis Pablo Ortega-Deballon Sophie Deguelte Serge Rohr Cécile Brigand Nicolas Meyer Benoit Romain |
| author_sort | Yannis Mesli |
| collection | DOAJ |
| description | Background The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment. Methods Patients with an ileostomy output ≥ 1.5 l/24 hours were included in this prospective, open, multicentre randomized trial. Patients were randomly allocated between treatment arms with either lanreotide (LAN) and antidiarrhoeal treatments (TAD) (LAN-TAD group) or antidiarrhoeal treatments only (TADS group). The primary outcome was ileostomy output after 72 days. The secondary endpoints were ileostomy output during the first 6 days, blood urea and creatinine values, hospital length of stay and serious adverse events. Results In the per-protocol analysis, there were nine patients in the control group (TADS) and six patients in the experimental group (TAD-LAN group). The stoma outputs at Day 3 (D3) in the experimental and control groups were 1,900 ± 855.7 mL and 1,728.6 ± 845.5 mL, respectively (p = 0.2). No differences were found concerning stoma output at D6, renal function, or hospital length of stay between the two groups. Conclusion The trial was prematurely stopped due to the low number of patients included. The question of the usefulness of somatostatin analogues in HOS persists, especially as the cost of this treatment is high, and there is a lack of evidence of its effectiveness. |
| first_indexed | 2024-03-12T00:31:02Z |
| format | Article |
| id | doaj.art-35489665593e4e13b5cc34297d38d2e3 |
| institution | Directory Open Access Journal |
| issn | 0894-1939 1521-0553 |
| language | English |
| last_indexed | 2024-03-12T00:31:02Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Investigative Surgery |
| spelling | doaj.art-35489665593e4e13b5cc34297d38d2e32023-09-15T10:12:29ZengTaylor & Francis GroupJournal of Investigative Surgery0894-19391521-05532021-11-0134121312131610.1080/08941939.2020.18008711800871Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment AloneYannis Mesli0Lise Holterbach1Jean-Baptiste Delhorme2Zaher Lakkis3Pablo Ortega-Deballon4Sophie Deguelte5Serge Rohr6Cécile Brigand7Nicolas Meyer8Benoit Romain9Department of Digestive Surgery, Strasbourg University HospitalPôle de Santé Publique - Santé au Travail - Groupe Methode en Recherche Clinique CHRU StrasbourgDepartment of Digestive Surgery, Strasbourg University HospitalDepartment of Digestive Surgery, Besançon University Hospital (Jean Minjoz)Department of Digestive Surgery, Dijon University HospitalDepartment of Digestive Surgery, Reims University HospitalDepartment of Digestive Surgery, Strasbourg University HospitalDepartment of Digestive Surgery, Strasbourg University HospitalPôle de Santé Publique - Santé au Travail - Groupe Methode en Recherche Clinique CHRU StrasbourgDepartment of Digestive Surgery, Strasbourg University HospitalBackground The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment. Methods Patients with an ileostomy output ≥ 1.5 l/24 hours were included in this prospective, open, multicentre randomized trial. Patients were randomly allocated between treatment arms with either lanreotide (LAN) and antidiarrhoeal treatments (TAD) (LAN-TAD group) or antidiarrhoeal treatments only (TADS group). The primary outcome was ileostomy output after 72 days. The secondary endpoints were ileostomy output during the first 6 days, blood urea and creatinine values, hospital length of stay and serious adverse events. Results In the per-protocol analysis, there were nine patients in the control group (TADS) and six patients in the experimental group (TAD-LAN group). The stoma outputs at Day 3 (D3) in the experimental and control groups were 1,900 ± 855.7 mL and 1,728.6 ± 845.5 mL, respectively (p = 0.2). No differences were found concerning stoma output at D6, renal function, or hospital length of stay between the two groups. Conclusion The trial was prematurely stopped due to the low number of patients included. The question of the usefulness of somatostatin analogues in HOS persists, especially as the cost of this treatment is high, and there is a lack of evidence of its effectiveness.http://dx.doi.org/10.1080/08941939.2020.1800871somatostatin analogueshigh-output stomadehydrationlanreotide |
| spellingShingle | Yannis Mesli Lise Holterbach Jean-Baptiste Delhorme Zaher Lakkis Pablo Ortega-Deballon Sophie Deguelte Serge Rohr Cécile Brigand Nicolas Meyer Benoit Romain Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone Journal of Investigative Surgery somatostatin analogues high-output stoma dehydration lanreotide |
| title | Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone |
| title_full | Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone |
| title_fullStr | Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone |
| title_full_unstemmed | Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone |
| title_short | Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone |
| title_sort | is lanreotide really useful in high output stoma comparison between lanreotide to conventional antidiarrheal treatment alone |
| topic | somatostatin analogues high-output stoma dehydration lanreotide |
| url | http://dx.doi.org/10.1080/08941939.2020.1800871 |
| work_keys_str_mv | AT yannismesli islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT liseholterbach islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT jeanbaptistedelhorme islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT zaherlakkis islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT pabloortegadeballon islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT sophiedeguelte islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT sergerohr islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT cecilebrigand islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT nicolasmeyer islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone AT benoitromain islanreotidereallyusefulinhighoutputstomacomparisonbetweenlanreotidetoconventionalantidiarrhealtreatmentalone |